Trial Profile

A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects With Primary Immunodeficiency Diseases (PID)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Dec 2024 According to a Takeda media release, company announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA in patients with agammaglobulinemia or hypogammaglobulinemia based on the data of NCT05150340, NCT05513586, NCT00814320 and NCT01175213 studies.
05 Sep 2023 Status changed from active, no longer recruiting to completed.
30 May 2023 Planned End Date changed from 30 Apr 2023 to 31 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com